Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results

Plus Therapeutics' stock surged 10.51% in pre-market trading on July 9, 2025, driven by significant developments in its clinical trials.

Plus Therapeutics has announced that its initial patients in the ReSPECT-LM dose optimization trial for REYOBIQ™ have been successfully treated. This trial is designed to identify the optimal dosing regimen that maximizes efficacy and safety, aligning with the FDA's Project Optimus. The company reported an 80% reduction in tumor size in brain cancer patients, highlighting the promising results of the treatment.

The successful treatment of initial patients in the ReSPECT-LM trial has generated substantial interest and optimism among investors. The company's focus on optimizing the dosing regimen for REYOBIQ™, a radiotherapy treatment for leptomeningeal metastases, has shown positive outcomes, contributing to the stock's pre-market surge.